• About us
• Contact

Advertisement

Organisation › Details

Takeda Ventures Inc. (TVI)

Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited (Takeda), and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based partnerships. TVI’s mission is to create strategic growth opportunities for Takeda by building, managing and investing in innovation-based companies. TVI partners with academic innovators, entrepreneurs and venture investors to create and nurture a portfolio of companies in an array of therapeutic areas, including oncology, gastroenterology and central nervous system disorders. *

 

	Start	2011-01-01 renamed
	Group	Takeda (Group)
	Predecessor	Takeda Research Investment Inc. (TRI)
	Industry	venture capital
	Industry 2	pharmaceutical
	Person	Punwani, Jayson (Takeda 201806 Partner at Takeda Ventures Inc)
	Person 2	Martin, Michael (Takeda 201411 Global Licensing + Business Development Search + Evaluation)
	Region	Palo Alto, CA
	Country	United States (USA)
	Street	435 Tasso Street Suite 300
	City	94301 Palo Alto, CA
	Tel	+1-650-328-2900
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona.
		Record changed: 2023-06-26

Advertisement

More documents for Takeda (Group)

• [1] Fresenius Medical Care AG & Co. KGaA. (12/5/22). "Press Release: Helen Giza to Take Over as Chief Executive Officer of Fresenius Medical Care"....
• [2] VectorY B.V.. (11/8/22). "Press Release: VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team". Amsterdam....
• [3] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
• [4] Takeda Pharmaceutical Co. Ltd.. (6/22/22). "Press Release: Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts". Cambridge, MA....
• [5] Takeda Pharmaceutical Co. Ltd.. (3/9/22). "Press Release: Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio". Osaka & Brisbane, CA....
• [6] Takeda Pharmaceutical Co. Ltd.. (2/3/22). "Press Release: Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace". Osaka & Cambridge, MA....
• [7] Poseida Therapeutics, Inc.. (1/10/22). "Press Release: Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen". San Diego, CA....
• [8] Takeda Pharmaceutical Co. Ltd.. (1/10/22). "Press Release: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (gd) T Cell Engager Therapies Targeting Solid Tumors". Osaka & London....
• [9] Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona....
• [10] Poseida Therapeutics, Inc.. (10/12/21). "Press Release: Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies". San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.